Across TCGA pan-cancer cohorts, RNU6ATAC42P RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RNU6ATAC42P’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RNU6ATAC42P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6ATAC42P is over-expressed in tumor, although a few such as ESCA and LUAD show the opposite, repressed pattern.

BRCA, ESCA, and LUAD are the cancer types where RNU6ATAC42P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6ATAC42P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	+0.154	.006	4	view →
ESCA	All	All	−0.994	.022	1	view →
LUAD	All	III,IV	−0.271	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RNU6ATAC42P RNA expression & survival · all RNU6ATAC42P data types